1. EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy- Naive Non–small Cell Lung Cancer 
Hideharu Kimura, MD, Kazuo Kasahara, MD, Kazuhiko Shibata, MD, Takashi Sone, MD, Akihiro Yoshimoto, MD, Toshiyuki Kita, MD, Yukari Ichikawa, MD, Yuko Waseda, MD, Kazuyoshi Watanabe, MD, Hiroki Shiarasaki, MD, Yoshihisa Ishiura, MD, Masayuki Mizuguchi, MD, Yasuto Nakatsumi, MD, Tatsuhiko Kashii, MD, Masashi Kobayashi, MD, Hideo Kunitoh, MD, Tomohide Tamura, MD, Kazuto Nishio, MD, Masaki Fujimura, MD, Shinji Nakao, MD 
Journal of Thoracic Oncology 
Volume 1, Issue 3, Pages (March 2006)
DOI: /S (15)31577-X
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Kaplan-Meier curve showing (A) overall survival and (B) time to progression in all patients.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15)31577-X)
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
(A) Detection of genomic EGFR in the serum of pretreatment patients. (B) The sequences of the PCR products from patient 19 (days 0 and 14) are shown. (C) PCR of the serum samples obtained on day 14. Serum-derived genomic DNA PCR was performed. Exon 19 of EGFR in serum obtained from the patients was amplified by PCR, and the products were detected using a Bioanalyzer. A second round of PCR (20 cycles) was performed when no band was detected in the first round of PCR (30 cycles). Row numbers indicate the patient number. *Band detected in the first round of PCR.
Journal of Thoracic Oncology 2006 1, DOI: ( /S (15)31577-X)
Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions